Incidence and survival of rare cancers in the US and Europe
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.3137
Abstract: Geographical variability of cancer burden was almost exclusively estimated for common cancers. Since rare cancers (RC) have become an area of priority for basic and clinical research and public health organizations, this paper provides, using… read more here.
Keywords: incidence; incidence survival; survival rare; rare cancers ... See more keywords
Current status and perspectives of patient-derived rare cancer models
Sign Up to like & getrecommendations! Published in 2020 at "Human Cell"
DOI: 10.1007/s13577-020-00391-1
Abstract: Malignancies with extremely low incidences, such as less than 6 per 100,000 people annually, are defined as rare cancers. Approximately 200 malignancies are classified in this category, therefore the total number of patients with rare… read more here.
Keywords: rare cancer; rare cancers; derived rare; cancer ... See more keywords
The new risk-sharing paradigm in rare cancers: Patient perspective
Sign Up to like & getrecommendations! Published in 2017 at "Journal of cancer policy"
DOI: 10.1016/j.jcpo.2017.03.007
Abstract: Abstract Advances in understanding the biology of rare cancers and in genomic technologies are reshaping drug development and are fostering patients' hopes because an increasing number of drugs are expected to be made available. However,… read more here.
Keywords: risk sharing; new risk; rare cancers; sharing paradigm ... See more keywords
Statistical Genomics in Rare Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Seminars in cancer biology"
DOI: 10.1016/j.semcancer.2019.08.021
Abstract: Rare cancers make of more than 20% of cancer cases. Due to the rare nature, less research has been conducted on rare cancers resulting in worse outcomes for patients with rare cancers compared to common… read more here.
Keywords: genomics rare; integration; rare cancer; rare cancers ... See more keywords
One-Drop Serum Screening Test for Anal Cancer in Men via Infrared Attenuated Total Reflection Spectroscopy.
Sign Up to like & getrecommendations! Published in 2022 at "Analytical chemistry"
DOI: 10.1021/acs.analchem.2c02439
Abstract: Rare cancers are a challenge for clinical practice, the treatment experience at major centers to which rare cancers are referred is limited and are the most difficult to diagnose. Research to identify causes or develop… read more here.
Keywords: one drop; spectroscopy; drop serum; rare cancers ... See more keywords
Estimating Country-Specific Incidence Rates of Rare Cancers: Comparative Performance Analysis of Modelling Approaches Using European Cancer Registry Data.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of epidemiology"
DOI: 10.1093/aje/kwab262
Abstract: Estimating incidence for rare cancers (RC) is challenging for exceptionally rare entities and in small populations. In a previous study, the RARECAREnet project provided Bayesian estimates of the expected number of RCs and their 95%… read more here.
Keywords: incidence; incidence rates; rare cancers; performance ... See more keywords
Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors
Sign Up to like & getrecommendations! Published in 2021 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noab209
Abstract: Abstract Clinical research for patients with rare cancers has been very challenging. First and foremost, patient accrual to clinical trials typically requires a network, cooperative group, or even international collaboration in order to achieve the… read more here.
Keywords: clinical trial; trial; challenges design; rare cancers ... See more keywords
Extrapolating evidence for molecularly targeted therapies from common to rare cancers: a scoping review of methodological guidance
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2021-058350
Abstract: Objectives Cancer is increasingly classified according to biomarkers that drive tumour growth and therapies developed to target them. In rare biomarker-defined cancers, randomised controlled trials to adequately assess targeted therapies may be infeasible. Extrapolating existing… read more here.
Keywords: targeted therapies; extrapolating evidence; biomarker; extrapolation ... See more keywords
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-3752
Abstract: Abstract Purpose: Patients with rare cancers (incidence less than 6 cases per 100,000 persons per year) commonly have less treatment opportunities and are understudied at the level of genomic targets. We hypothesized that patients with… read more here.
Keywords: benefit; drug; treatment; rare cancers ... See more keywords
Abstract 4801: Potential of mebendazole as an anti-tumor agent for adenoid cystic carcinoma and other rare cancers
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4801
Abstract: Adenoid Cystic Carcinoma (ACC) is a rare adenocarcinoma arising most commonly in the major and minor salivary glands of the head and neck. Despite a deepening understanding of the molecular events that lead to sustained… read more here.
Keywords: tumor; treatment; anti tumor; rare cancers ... See more keywords
Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct083
Abstract: Beyond melanoma, BRAFV600E alterations are prevalent across multiple tumors. We conducted a basket trial (NCT02034110) to assess efficacy and safety of oral BRAF inhibitor dabrafenib (150 mg BD) plus MEK inhibitor trametinib (2 mg OD)… read more here.
Keywords: reached reached; safety; rare cancers; brafv600e mutated ... See more keywords